Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
Zymeworks Announces Participation In Upcoming Investor Conferences
Zymeworks Showcases New and Updated Clinical Data for Zanidatamab at ASCO 2023
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals and BeiGene, new and updated data from two ongoing clinical trials evaluating zanidatamab, a HER2-targeted bispecific antibody for the treatment of solid tumors, at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2 to June 6 in Chicago, IL. Results […]
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
Zymeworks Announces Participation In Upcoming Investor Conferences
Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting
Zymeworks To Host First Quarter 2023 Results Conference Call
Zymeworks Announces Appointment of Derek J. Miller to its Board of Directors
Zymeworks Announces Participation In Upcoming Investor Conferences
Zymeworks To Present Updated Data On Multiple Product Candidates At The American Association For Cancer Research (AACR) Annual Meeting
Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results
